Effects of Sepiapterin Supplementation and NOS Inhibition on Glucocorticoid-Induced Hypertension

被引:10
|
作者
Thida, Mya [1 ]
Earl, John [2 ]
Zhao, Yan [3 ]
Wang, Hans [1 ]
Tse, Chi S. [1 ]
Vickers, Janine J. [1 ]
Sutton, Matthew [1 ]
Ong, Sharon L. H. [1 ]
Mori, Trevor A. [3 ]
Croft, Kevin D. [3 ]
Whitworth, Judith A. [1 ]
Zhang, Yi [1 ]
机构
[1] Australian Natl Univ, John Curtin Sch Med Res, High Blood Pressure Res Unit, Canberra, ACT 2601, Australia
[2] Childrens Hosp Westmead, Sydney, NSW, Australia
[3] Univ Western Australia, Sch Med & Pharmacol, Perth, WA 6009, Australia
关键词
blood pressure; endothelial nitric oxide synthase; glucocorticoid; hypertension; N-nitro-L-arginine (NOLA); rat; sepiapterin; NITRIC-OXIDE SYNTHASE; DEXAMETHASONE-INDUCED HYPERTENSION; HORMONE-INDUCED HYPERTENSION; ADRENOCORTICOTROPIN-INDUCED HYPERTENSION; GTP-CYCLOHYDROLASE-I; L-ARGININE PREVENTS; BLOOD-PRESSURE; DOWN-REGULATION; RAT; TETRAHYDROBIOPTERIN;
D O I
10.1038/ajh.2010.27
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
BACKGROUND Glucocorticoid-induced hypertension is associated with imbalance between nitric oxide (NO) and superoxide. One of the pathways that causes this imbalance is endothelial NO synthase (eNOS) uncoupling. In the present study, adrenocorticotrophic hormone (ACTH)- and dexamethasone-treated rats were further treated with sepiapterin, a precursor of tetrahydrobiopterin, or N-nitro-L-arginine (NOLA), an inhibitor of NOS, to investigate the role of eNOS uncoupling in glucocorticoid-induced hypertension. METHODS Male Sprague-Dawley (SD) rats (n = 7-13/group) were treated with either sepiapterin (5 mg/kg/day, IP) or saline (sham) 4 days before and during ACTH (0.2 mg/kg/day, SC), dexamethasone (0.03 mg/kg/day, SC), or saline treatment. NOLA (0.4 mg/ml in drinking water) was given to rats 4 days before and during dexamethasone treatment. Systolic blood pressure (SBP) was measured by the tail-cuff method. RESULTS Both ACTH (116 +/- 2 to 135 +/- 3 mm Hg (mean s.e.m.), P < 0.001) and dexamethasone (114 +/- 4 to 133 +/- 3 mm Hg, P < 0.0005) increased SBP. Sepiapterin alone did not alter SBP. Sepiapterin did not prevent ACTH- (129 +/- 4 mm Hg, NS) or dexamethasone-induced hypertension (135 +/- 3 mm Hg, NS), although plasma total biopterin concentrations were increased. NOLA increased SBP in rats prior to dexamethasone or saline treatment. NOLA further increased SBP in both saline (133 +/- 4 to 157 +/- 3 mm Hg, P < 0.05) and dexamethasone-treated rats (135 5 to 170 6 mm Hg, P < 0.05). ACTH and dexamethasone increased plasma F-2-isoprostane concentrations. Neither sepiapterin nor NOLA significantly affected this marker of oxidative stress. CONCLUSION Sepiapterin did not prevent ACTH- or dexamethasone-induced hypertension. NOLA exacerbated dexamethasone-induced hypertension. These data suggest that eNOS uncoupling does not play a major role in the genesis of glucocorticoid-induced hypertension in the rat.
引用
收藏
页码:569 / 574
页数:6
相关论文
共 50 条
  • [41] Glucocorticoid-induced osteonecrosis
    Robert S. Weinstein
    Endocrine, 2012, 41 : 183 - 190
  • [42] Glucocorticoid-induced myopathy
    Rodrigues Pereira, Rosa Maria
    de Carvalho, Jozelio Freire
    JOINT BONE SPINE, 2011, 78 (01) : 41 - 44
  • [43] Glucocorticoid-induced osteoporosis
    Tamura, Y
    Okinaga, H
    Takami, H
    BIOMEDICINE & PHARMACOTHERAPY, 2004, 58 (09) : 500 - 504
  • [44] Glucocorticoid-induced hyperglycemia
    Perez, Antonio
    Jansen-Chaparro, Sergio
    Saigi, Ignasi
    Rosa Bernal-Lopez, M.
    Minambres, Inka
    Gomez-Huelgas, Ricardo
    JOURNAL OF DIABETES, 2014, 6 (01) : 9 - 20
  • [45] Glucocorticoid-induced osteoporosis
    Cortet, Bernard
    ANNALES D ENDOCRINOLOGIE, 2023, 84 (03) : 373
  • [46] Glucocorticoid-induced osteoporosis
    Compston, J
    HORMONE RESEARCH, 2003, 60 : 77 - 79
  • [47] Glucocorticoid-induced osteoporosis
    Kumar, R
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2001, 10 (05): : 589 - 595
  • [48] GLUCOCORTICOID-INDUCED OSTEOPOROSIS
    LUKERT, BP
    RAISZ, LG
    RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 1994, 20 (03) : 629 - 650
  • [49] Glucocorticoid-induced Osteoporosis
    Lamersdorf, A.
    Siggelkow, H.
    OSTEOLOGIE, 2016, 25 (04) : 269 - 272
  • [50] GLUCOCORTICOID-INDUCED OSTEOPOROSIS
    GENNARI, C
    CLINICAL ENDOCRINOLOGY, 1994, 41 (03) : 273 - 274